Li Meina, Keenan Christine R, Lopez-Campos Guillermo, Mangum Jonathan E, Chen Qianyu, Prodanovic Danica, Xia Yuxiu C, Langenbach Shenna Y, Harris Trudi, Hofferek Vinzenz, Reid Gavin E, Stewart Alastair G
Department of Pharmacology & Therapeutics, School of Biomedical Science, University of Melbourne, Parkville, VIC 3010, Australia.
Health and Biomedical Informatics Centre, Melbourne Medical School, University of Melbourne, Parkville, VIC 3010, Australia; Centre for Experimental Medicine, Queen's University of Belfast, Belfast BT9 7BL, UK.
iScience. 2019 Feb 22;12:232-246. doi: 10.1016/j.isci.2019.01.023. Epub 2019 Jan 21.
Impaired therapeutic responses to anti-inflammatory glucocorticoids (GC) in chronic respiratory diseases are partly attributable to interleukins and transforming growth factor β1 (TGF-β1). However, previous efforts to prevent induction of GC insensitivity by targeting established canonical and non-canonical TGF-β1 pathways have been unsuccessful. Here we elucidate a TGF-β1 signaling pathway modulating GC activity that involves LIM domain kinase 2-mediated phosphorylation of cofilin1. Severe, steroid-resistant asthmatic airway epithelium showed increased levels of immunoreactive phospho-cofilin1. Phospho-cofilin1 was implicated in the activation of phospholipase D (PLD) to generate the effector(s) (lyso)phosphatidic acid, which mimics the TGF-β1-induced GC insensitivity. TGF-β1 induction of the nuclear hormone receptor corepressor, SMRT (NCOR2), was dependent on cofilin1 and PLD activities. Depletion of SMRT prevented GC insensitivity. This pathway for GC insensitivity offers several promising drug targets that potentially enable a safer approach to the modulation of TGF-β1 in chronic inflammatory diseases than is afforded by global TGF-β1 inhibition.
慢性呼吸道疾病中对抗炎糖皮质激素(GC)的治疗反应受损部分归因于白细胞介素和转化生长因子β1(TGF-β1)。然而,以往通过靶向已确立的经典和非经典TGF-β1途径来预防GC不敏感诱导的努力均未成功。在此,我们阐明了一条调节GC活性的TGF-β1信号通路,该通路涉及LIM结构域激酶2介导的丝切蛋白1磷酸化。重度、类固醇抵抗性哮喘气道上皮中免疫反应性磷酸化丝切蛋白1水平升高。磷酸化丝切蛋白1与磷脂酶D(PLD)的激活有关,以生成效应物(溶血)磷脂酸,后者模拟TGF-β1诱导的GC不敏感。TGF-β1诱导核激素受体共抑制因子SMRT(NCOR2)依赖于丝切蛋白1和PLD活性。SMRT的缺失可防止GC不敏感。这种GC不敏感途径提供了几个有前景的药物靶点,与全面抑制TGF-β1相比,这可能为慢性炎症性疾病中调节TGF-β1提供一种更安全的方法。